Hemcheck's Newsletter - October 2020

Welcome to the October Newsletter from Hemcheck

Hemcheck has continued on its journey in October. A very positive event during October was the signing of our first University hospital customer, in Tartu University hospital in Estonia. This was the result of a process that included, among other things, a series of product tests in different settings in the hospital.

Tartu is an important customer in its own right, but more generally we see increasing potential of additional customers with every new customer we sign. And very importantly, the possibility of helping more healthcare providers and patients in reducing the issues related to hemolysis.

On other fronts we have e.g. continued our development work of the new product for the blood gas market and the market development work e.g. together with our partners within the Bridgehead Europe programme.

In this newsletter you can read more about our agreement with Tartu University hospital in Estonia and our other current sales and marketing efforts.

Enjoy the reading!

Joen Averstad, CEO
201102 Hemcheck NFKK Bild 1

Agreement signed with Tartu University Hospital in Estonia

Hemcheck recently signed a subscription agreement with Tartu University Hospital regarding delivery of readers and hemolysis tests for vacuum tubes for usage at the oncology and hematology clinic. The agreement was signed after a series of product tests showing good product performance as well as a high degree of satisfaction and support among the medical staff for the concept. The implementation of the solution at Tartu University Hospital serves as a good marker for the attractiveness of the product concept and is implemented aiming to improve the flows of samples and patients, reduce turnaround time, decrease staff workload, and hence increase patient safety and save related costs for the hospital.

Read more

Current sales and marketing efforts

The focus of our sales and marketing efforts continue to be, as earlier communicated, potential customers and key stakeholders within laboratory and emergency medicine, but also other secondary care departments and privately run healthcare organisations.

Many of our efforts have continued as earlier but the pandemic has affected our sales routines since e.g. all industry fairs/conferences have been postponed/cancelled, some tests have been postponed and it is difficult to have in-person meetings. Therefore the sales routines have evolved to meet the market needs in new and more effective ways, e.g.:
  • Sales related to fairs and crowded events have been and will be replaced by an increased presence in other media and contexts, e.g. online events, social media, collaborations with industry organisations such as NFKK, IFCC, and EFLM, as well as using new digital sales and marketing tools.
  • To facilitate user training and follow up during the pandemic, we have shifted to digital training including e.g. instruction videos for our products. Even after the pandemic, this will be an important complement to our in person user training.
During the pandemic, we have been able to have progress and we have many different ongoing/planned user tests, studies and customer discussions, across Sweden, other parts of Europe, e.g. France, the Netherlands and Spain, and the Middle East. This concerns both the v-Test and s-Test. We are also continuing our Nordic collaboration with Siemens. Most regular blood gas tenders have been postponed during the pandemic but we have ongoing dialogues and plans for joint activities and cooperative efforts, where our point of care hemolysis detection solution is a unique offering.

Peter Andersson, Manager of Sales & Marketing
Contact Us
Hemcheck Sweden AB
Karlstads universitet
Universitetsgatan 2
651 88 Karlstad